BCL2 and Miyoshi myopathy: This biological plasticity in usage of one or both anti-apoptotic proteins by MM cells presents a unique challenge in clinical development of drugs, where inhibition of the right Bcl-2 family member at the right time is the key to crippling tumor cell survival programming.